Home :: Medication :: Paraplatin

Latest Paraplatin News

Doxil®/Eloxatin® May Provide a Treatment Option in Advanced ... - Cancer Consultants (press release)

Researchers in Italy conducted this multi-center phase II study to further evaluate the efficacy and safety of the combination of Doxil and Eloxatin for the treatment of patients with recurrent ovarian Cancer. Participants in the study included women with recurrent ovarian Cancer who had previously been treated with a regimen containing a platinum agent (Paraplatin® [carboplatin] or Platinol® [cisplatin]).Anticancer responses occurred in 54% of patients.Anticancer responses occurred in 67% of patients who had achieved an anticancer response for at least 6 months following prior platinum-based therapy.Anticancer responses occurred in 29% of patients who experienced Cancer progression within 6 months of treatment following prior platinum-based therapy.Median overall survival Was nearly 16 months.Median time to Cancer progression Was 7.3 months.Most side effects were mild and manageable.

Paraplatin

No Ebay Marketplace Listings Found